Integrating Network Pharmacology and Experimental Verification to Explore the Targets for Colchicine against Coronary In-Stent Restenosis - PubMed
3 hours ago
- #Network Pharmacology
- #In-Stent Restenosis
- #Colchicine
- Colchicine shows potential in reducing In-Stent Restenosis (ISR) through multi-target mechanisms.
- 30 overlapping targets were identified, enriched in atherosclerosis-related and inflammatory pathways.
- Key targets include TGF-β1, ICAM1, and VCAM1, central to extracellular matrix organization and inflammation.
- Molecular docking confirmed strong binding affinity between colchicine and these targets.
- In vivo studies showed colchicine reduced neointimal hyperplasia and downregulated TGF-β1, ICAM1, and VCAM1.
- Colchicine modulates both inflammatory and fibrotic processes, offering dual therapeutic advantages.
- Further research is needed to optimize drug delivery and compare colchicine with standard therapies.